Superior Response of CAP-PRRT of G3 NET When Switching to the Somatostatin Receptor Antagonist LM3: Intraindividual Proof-of-concept
Speicher T, Burgard C, Rosar F, Bastian M, Bartholomä M, Maus S, Ezziddin S (2025)
Publication Type: Journal article
Publication year: 2025
Journal
Book Volume: 50
Pages Range: 981-982
Journal Issue: 10
DOI: 10.1097/RLU.0000000000005938
Abstract
We present a 67-year-old man with inoperable metastatic G3 NET of the pancreas. The lesions were intensely positive in [68Ga]Ga-DOTATOC PET/CT and only weakly positive in the supplementary [18F]-FDG PET/CT. Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA-octreotate, after longstanding efficacy with repetitive retreatments over 7 years, eventually resulted only in disease stabilization without partial regression of lesions. After switching PRRT to the somatostatin receptor antagonist [177Lu]Lu-DOTA-LM3, a marked therapy response was observed, in remarkable contrast to the stable disease effect of 177Lu-octreotate seen right before. This interesting image illustrates the superior therapeutic efficacy of somatostatin antagonist PRRT over agonist-based PRRT.
Involved external institutions
Germany (DE)How to cite
APA:
Speicher, T., Burgard, C., Rosar, F., Bastian, M., Bartholomä, M., Maus, S., & Ezziddin, S. (2025). Superior Response of CAP-PRRT of G3 NET When Switching to the Somatostatin Receptor Antagonist LM3: Intraindividual Proof-of-concept. Clinical Nuclear Medicine, 50(10), 981-982. https://doi.org/10.1097/RLU.0000000000005938
MLA:
Speicher, Tilman, et al. "Superior Response of CAP-PRRT of G3 NET When Switching to the Somatostatin Receptor Antagonist LM3: Intraindividual Proof-of-concept." Clinical Nuclear Medicine 50.10 (2025): 981-982.
BibTeX: Download